Nishant Rastogi

Nishant Rastogi is a seasoned professional in the life sciences sector, currently serving as the VP and Head of Transactions at New Rhein Healthcare Investors since July 2018, where the firm focuses on private equity in biotech and medtech investments. In addition to this role, Nishant is a member of the Board of Directors at Corsair Pharma and serves as a Board Observer for multiple companies, including Alveus Therapeutics, Butterfly Medical, Neuraptive Therapeutics, and previously American Injectables and FineHeart. Nishant's educational background includes a Bachelor of Arts in Economics and Mathematical Finance from Dartmouth College, an accelerated MBA in Finance and Health Enterprise Management from Northwestern University’s Kellogg School of Management, and additional certifications from Harvard Medical School and Yale School of Public Health, among other institutions.